Hepatitis A virus seroprevalence by age and world region, 1990 and 2005 - PubMed (original) (raw)
Review
. 2010 Sep 24;28(41):6653-7.
doi: 10.1016/j.vaccine.2010.08.037. Epub 2010 Aug 17.
Affiliations
- PMID: 20723630
- DOI: 10.1016/j.vaccine.2010.08.037
Review
Hepatitis A virus seroprevalence by age and world region, 1990 and 2005
Kathryn H Jacobsen et al. Vaccine. 2010.
Abstract
Objective: To estimate current age-specific rates of immunity to hepatitis A virus (HAV) in world regions by conducting a systematic review and meta-analysis of published data. The estimation of the global burden of hepatitis A and policies for public health control are dependent on an understanding of the changing epidemiology of this viral infection.
Methods: Age-specific IgG anti-HAV seroprevalence data from more than 500 published articles were pooled and used to fit estimated age-seroprevalence curves in 1990 and 2005 for each of 21 world regions (as defined by the Global Burden of Disease 2010 Study).
Findings: High-income regions (Western Europe, Australia, New Zealand, Canada, the United States, Japan, the Republic of Korea, and Singapore) have very low HAV endemicity levels and a high proportion of susceptible adults, low-income regions (sub-Saharan Africa and parts of South Asia) have high endemicity levels and almost no susceptible adolescents and adults, and most middle-income regions have a mix of intermediate and low endemicity levels.
Conclusion: Anti-HAV prevalence estimates in this analysis suggest that middle-income regions in Asia, Latin America, Eastern Europe, and the Middle East currently have an intermediate or low level of endemicity. The countries in these regions may have an increasing burden of disease from hepatitis A, and may benefit from new or expanded vaccination programs.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
- A new method for imputing country-level estimates of hepatitis A virus endemicity levels in the Eastern Mediterranean region.
Itani T, Jacobsen KH, Nguyen T, Wiktor SZ. Itani T, et al. Vaccine. 2014 Oct 21;32(46):6067-74. doi: 10.1016/j.vaccine.2014.09.006. Epub 2014 Sep 16. Vaccine. 2014. PMID: 25236586 Review. - Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations.
Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, Aydogan A, Koc A, Yasa O, Köseoğlu M, Onal K, Hacimustafaoglu M, Celebi S. Ceyhan M, et al. J Viral Hepat. 2008 Oct;15 Suppl 2:69-72. doi: 10.1111/j.1365-2893.2008.01034.x. J Viral Hepat. 2008. PMID: 18837839 - Hepatitis A virus seroprevalence in South Africa - Estimates using routine laboratory data, 2005-2015.
Haeri Mazanderani A, Motaze NV, McCarthy K, Suchard M, du Plessis NM. Haeri Mazanderani A, et al. PLoS One. 2019 Jun 26;14(6):e0216033. doi: 10.1371/journal.pone.0216033. eCollection 2019. PLoS One. 2019. PMID: 31242191 Free PMC article. - Seroprevalence of hepatitis A virus in a cross-sectional study in Mexico: Implications for hepatitis A vaccination.
Lazcano-Ponce E, Conde-Gonzalez C, Rojas R, DeAntonio R, Romano-Mazzotti L, Cervantes Y, Ortega-Barria E. Lazcano-Ponce E, et al. Hum Vaccin Immunother. 2013 Feb;9(2):375-81. doi: 10.4161/hv.22774. Epub 2013 Jan 4. Hum Vaccin Immunother. 2013. PMID: 23291940 Free PMC article. - Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Mohd Hanafiah K, et al. Hepatology. 2013 Apr;57(4):1333-42. doi: 10.1002/hep.26141. Epub 2013 Feb 4. Hepatology. 2013. PMID: 23172780 Review.
Cited by
- Unveiling the Burden of Hepatitis A in Salerno, Italy: A Comprehensive 9-Year Retrospective Study (2015-2023) on the Seroprevalence of HAV Antibodies and Age/Sex Distribution.
Serretiello E, Iervolino D, Di Siervi G, Gallo L, Bernardi FF, Pagliano P, Boccia G, Folliero V, Franci G, Rinaldi L. Serretiello E, et al. J Clin Med. 2024 Sep 18;13(18):5534. doi: 10.3390/jcm13185534. J Clin Med. 2024. PMID: 39337021 Free PMC article. - Children With Hepatitis in a Tertiary Care Center in Nepal: A Prospective Observational Study.
Shrestha B, Singh U, Karmacharya K, Singh S. Shrestha B, et al. Glob Pediatr Health. 2024 Sep 6;11:2333794X241274713. doi: 10.1177/2333794X241274713. eCollection 2024. Glob Pediatr Health. 2024. PMID: 39246303 Free PMC article. - Healthcare and Epidemiological Surveillance Costs of Hepatitis A Outbreaks in Spain in Regions with and without Universal Hepatitis A Vaccination of Children during 2010-2018.
Plans-Rubió P, Pericas C, Avellon AM, Izquierdo C, Martínez A, Torner N, Martínez A, Borrás E, Roig F, Godoy P, Rius C. Plans-Rubió P, et al. Vaccines (Basel). 2024 Jun 11;12(6):648. doi: 10.3390/vaccines12060648. Vaccines (Basel). 2024. PMID: 38932377 Free PMC article. - Seroprevalence and Shifting Endemicities of Hepatitis A Virus Infection in Two Different Geographical Areas in the Philippines.
Carlos JC, Quinones VMT, Adversario MPL, Nailes JM, Songco JC, Garcia DR, Cacayorin MG, Cero MPV, Benedicto-Delfin MPA, Blanco MCC, Natividad NS, Bernabe JD, Chacon HCT, Ascue RAC, Paggao JNK, Comendador LOP, Hernandez-Suarez G, Guzman-Holst A. Carlos JC, et al. Infect Dis Ther. 2024 May;13(5):1019-1035. doi: 10.1007/s40121-024-00955-w. Epub 2024 Apr 5. Infect Dis Ther. 2024. PMID: 38578515 Free PMC article. - The Shifting Epidemiology of Hepatitis A in the World Health Organization Western Pacific Region.
Gloriani NG, de Paz-Silava SLM, Allison RD, Takashima Y, Avagyan T. Gloriani NG, et al. Vaccines (Basel). 2024 Feb 16;12(2):204. doi: 10.3390/vaccines12020204. Vaccines (Basel). 2024. PMID: 38400187 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical